Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review

Camilloni, Barbara; Basileo, Michela; Valente, Stefano; Nunzi, E.; Iorio, Anna Maria

doi:10.1080/21645515.2015.1011562

Cited by 56 publications

(35 citation statements)

References 66 publications

(182 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Classical vaccination uses injection to administer vaccines directly into subcutaneous fat or muscle. However, recent studies have revealed that vaccination by the intradermal route is more effective, because numerous populations of immune cells are found more in the epidermis and dermis than in the subcutaneous tissue . The immune‐related cells in the skin include LCs, dendritic epidermal γδ T cells and CD8 + tissue‐resident memory T cells in the epidermis, as well as dDC subsets, dermal γδ T cells, mast cells and CD4 + tissue‐resident memory T cells in the dermis .…”

Section: Application Of S/o Nanodispersion Systemsmentioning

confidence: 99%

Solid‐in‐oil nanodispersions for transdermal drug delivery systems

Kitaoka

Wakabayashi

Kamiya

et al. 2016

Biotechnology Journal

View full text Add to dashboard Cite

Transdermal administration of drugs has advantages over conventional oral administration or administration using injection equipment. The route of administration reduces the opportunity for drug evacuation before systemic circulation, and enables long‐lasting drug administration at a modest body concentration. In addition, the skin is an attractive route for vaccination, because there are many immune cells in the skin. Recently, solid‐in‐oil nanodisperison (S/O) technique has demonstrated to deliver cosmetic and pharmaceutical bioactives efficiently through the skin. S/O nanodispersions are nanosized drug carriers designed to overcome the skin barrier. This review discusses the rationale for preparation of efficient and stable S/O nanodispersions, as well as application examples in cosmetic and pharmaceutical materials including vaccines. Drug administration using a patch is user‐friendly, and may improve patient compliance. The technique is a potent transcutaneous immunization method without needles.

show abstract

Section: Application Of S/o Nanodispersion Systemsmentioning

confidence: 99%

Solid‐in‐oil nanodispersions for transdermal drug delivery systems

Kitaoka

Wakabayashi

Kamiya

et al. 2016

Biotechnology Journal

View full text Add to dashboard Cite

show abstract

“…Its mode of action is linked to local proinflammatory cytokine production mediating cell recruitment, stimulating antigen uptake and cell differentiation of DCs as well as improving B cell differentiation and their persistence in germinal centers (72). Addition of MF59 R to a subunit influenza vaccine can enhance antibody production compared to standard vaccines even against drifted strains such as H3N2, that is linked to severe disease in the elderly (73)(74)(75). Additionally, use of MF59 R adjuvanted influenza vaccines can lead to expansion of predominantly IL-2 producing CD4 + lymphocytes against pandemic H5N1 compared to a non-adjuvanted vaccine (76).…”

Section: Adjuvants For Influenza Vaccinesmentioning

confidence: 99%

Vaccines to Prevent Infectious Diseases in the Older Population: Immunological Challenges and Future Perspectives

Wagner

Weinberger

2020

Front. Immunol.

View full text Add to dashboard Cite

Infectious diseases are a major cause for morbidity and mortality in the older population. Demographic changes will lead to increasing numbers of older persons over the next decades. Prevention of infections becomes increasingly important to ensure healthy aging for the individual, and to alleviate the socioeconomic burden for societies. Undoubtedly, vaccines are the most efficient health care measure to prevent infections. Age-associated changes of the immune system are responsible for decreased immunogenicity and clinical efficacy of most currently used vaccines in older age. Efficacy of standard influenza vaccines is only 30-50% in the older population. Several approaches, such as higher antigen dose, use of MF59 as adjuvant and intradermal administration have been implemented in order to specifically target the aged immune system. The use of a 23-valent polysaccharide vaccine against Streptococcus pneumoniae has been amended by a 13-valent conjugated pneumococcal vaccine originally developed for young children several years ago to overcome at least some of the limitations of the T cell-independent polysaccharide antigens, but still is only approximately 50% protective against pneumonia. A liveattenuated vaccine against herpes zoster, which has been available for several years, demonstrated efficacy of 51% against herpes zoster and 67% against post-herpetic neuralgia. Protection was lower in the very old and decreased several years after vaccination. Recently, a recombinant vaccine containing the viral glycoprotein gE and the novel adjuvant AS01B has been licensed. Phase III studies demonstrated efficacy against herpes zoster of approx. 90% even in the oldest age groups after administration of two doses and many countries now recommend the preferential use of this vaccine. There are still many infectious diseases causing substantial morbidity in the older population, for which no vaccines are available so far. Extensive research is ongoing to develop vaccines against novel targets with several vaccine candidates already being clinically tested, which have the potential to substantially reduce health care costs and to save many lives. In addition to the development of novel and improved vaccines, which specifically target the aged immune system, it is also important to improve uptake of the existing vaccines in order to protect the vulnerable, older population.

show abstract

“…C'est en particulier ce qui est recherché au cours du développement d'un vaccin par le design vaccinal [22]. En effet, de nouvelles formulations de vaccin contre la grippe (virus atténué, ajout d'adjuvant ou changement de voie d'administration) ont permis d'augmenter l'immunité anti-grippale afin d'améliorer la protection ou même d'induire une immunité cellulaire chez les individus immunodéprimés [23][24]. Chez l'homme, la voie intramusculaire conduit à une protection modérée et variée contre le virus de la grippe via l'induction d'une réponse humorale.…”

Section: Biologie Des Systèmes : Sonder La Dynamique Immunologique Apunclassified

Prédire la réponse à la vaccination contre la grippe

Gonçalves

Combadière

2020

Med Sci (Paris)

View full text Add to dashboard Cite

La vaccination est l’un des progrès majeurs de la médecine moderne. Mais afin d’améliorer l’efficacité des vaccins existants et d’en élaborer de nouveaux, nous devons mieux connaître les mécanismes d’action à l’origine de l’immunité protectrice et les stratégies vaccinales permettant d’induire une défense durable. La voie cutanée est une stratégie de vaccination importante, en raison de la richesse qu’elle présente en cellules de l’immunité innée qui ont un rôle clé dans la qualité, l’intensité et la persistance des réponses adaptatives qu’elles induisent. L’intégration des données biologiques obtenues au cours d’un essai clinique de vaccination antigrippale nous donne un aperçu de l’impact de la voie d’immunisation et de la signature innée sur la qualité des réponses immunitaires.

show abstract

Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review

Cited by 56 publications

References 66 publications

Solid‐in‐oil nanodispersions for transdermal drug delivery systems

Solid‐in‐oil nanodispersions for transdermal drug delivery systems

Vaccines to Prevent Infectious Diseases in the Older Population: Immunological Challenges and Future Perspectives

Prédire la réponse à la vaccination contre la grippe

Contact Info

Product

Resources

About